Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective vigilantly but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last several shares. My first CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire job interview that I came away with an inadequate opinion of the business.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, although the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology and linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and also the first new drug application endorsement ($5 million), and even royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and multiple indications, it’s this individual treatments and a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its website (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple presentations and multiple publications.

Can all this be smoke and mirrors? That’s a question I have been asking myself through the really beginning of the interest of mine in this particular business. Judging with the multiples of thousands of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or maybe some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *